OwenJL, VakhariaPP, SilverbergJI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol., 2018; 19(3):293–302.
2.
SimpsonEL, PappKA, BlauveltA, et al.Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol., 2022; 158(4):404–413.
3.
JohnsonH, GuentherJ, AdlerBL, et al.Janus kinase inhibitors: A promising therapeutic option for allergic contact dermatitis. Cutis., 2023; 111(2):92–105.
4.
McPhieML, PrattMD, KirchhofMG. Negative patch test findings after initiation of upadacitinib: A case report. SAGE Open Med Case Rep. 2024; 12:2050313X241304949.
5.
Ch’enPY, Al-SaedyM, SongEJ. Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis. JAAD Case Rep. 2024; 44:20–22.
